Molecular tests for tuberculosis (TB) have the potential to help reach the three million people
with TB who are undiagnosed or not reported each year and to improve the quality of care …

Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Background Active pulmonary tuberculosis is difficult to diagnose and treatment response is
difficult to effectively monitor. A WHO consensus statement has called for new non-sputum …

Rationale: Contacts of patients with tuberculosis (TB) constitute an important target
population for preventive measures because they are at high risk of infection with …

The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the
diagnostic landscape of tuberculosis (TB). More than 16 million tests have been performed …

Tuberculosis (TB) remains a leading cause of death globally. Dissemination of TB to the
brain results in the most severe form of extrapulmonary TB, tuberculous meningitis (TBM) …

New approaches to control the spread of tuberculosis (TB) are needed, including tools to
predict development of active TB from latent TB infection (LTBI). Recent studies have …

Tuberculosis (TB) remains a devastating disease, yet despite its enormous toll on global
health, tools to control TB are insufficient and often outdated. TB Biomarkers (TB‐BM) would …

In 2015, tuberculosis remains a major global health problem, and drug-resistant tuberculosis
is a growing threat. Although tuberculosis diagnosis in many countries is still reliant on older …

Background Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health
Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely …